Stent fracture and restenosis of a paclitaxel-eluting stent.

Michalis Hamilos; Michail I. Papafaklis; Jürgen Ligthart; Patrick W. Serruys; Georgios Sianos

Related publications

Article2006

Stent fracture and restenosis of a paclitaxel-eluting stent.

Michalis Hamilos, Michail I. Papafaklis, Jürgen Ligthart, Patrick W. Serruys, Georgios Sianos

PubMed

Article2003

Stent fracture and restenosis in the drug‐eluting stent era

Georgios Sianos, Sjoerd H. Hofma, Jürgen Ligthart, Francesco Saia, Angela Hoye, Pedro A. Lemos, Patrick W. Serruys

Catheterization and Cardiovascular Interventions

Article2006

Paclitaxel-eluting stent restenosis shows three-layer appearance by optical coherence tomography.

Shuzou Tanimoto, Jiro Aoki, Patrick W. Serruys, Evelyn Regar

PubMed

Article2008

Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial

Ahmed A. Khattab, Gert Richardt, Vitali Verin, Henning Kelbæk, Carlos Macaya, Jacques Berland, Karine Miquel‐Hébert, Cécile Dorange, Patrick W. Serruys

EuroIntervention

Article2003

Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis

J. Eduardo Sousa, Marco A. Costa, Alexandre Abizaid, Amanda G. M. R. Sousa, Fausto Feres, Luiz Alberto Mattos, Marinella Centemero, Galo Maldonado, Alexandre Abizaid, Ibraim Pinto, Robert Falotico, Judith Jaeger, Jeffrey J. Popma, Patrick W. Serruys

Circulation

Stent fracture and restenosis of a paclitaxel-eluting stent.

Discussion(0)

Related publications

Stent fracture and restenosis of a paclitaxel-eluting stent.

Stent fracture and restenosis in the drug‐eluting stent era

Paclitaxel-eluting stent restenosis shows three-layer appearance by optical coherence tomography.

Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial

Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis